Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Advaxis files marketing application in Europe for lead candidate in second-line cervical cancer

Published 02/13/2018, 10:36 AM
Updated 02/13/2018, 10:36 AM
© Reuters.  Advaxis files marketing application in Europe for lead candidate in second-line cervical cancer
  • Advaxis (ADXS +0.4%) files an application in Europe seeking conditional approval for lead candidate axalimogene filolisbac (AF) for the treatment of adult women with recurrent/metastatic cervical cancer who progress beyond first-line treatment.
  • The data supporting the application was generated in the Phase 2 GOG-0265 study that showed treatment with AF extended survival 55%.
  • Axalimogene filolisbac is an immunotherapy based on the company's Lm Technology, which uses live attenuated bioengineered Listeria bacteria to deliver a fusion protein inside cancer cells which then stimulates the immune system to attack the cancer.
  • Previously: Advaxis lead product candidate increases survival in mid-stage study in treatment-resistant cervical cancer (Oct. 24, 2016)
  • Now read: In This Stock Market, It's Time To Declare War On Biotech Bagholding


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.